HER2放射性分子探针应用于肿瘤诊疗的研究进展

Advances in the application of HER2 radioactive molecular probes for tumour diagnosis and treatment

人表皮生长因子受体2(HER2)在多种肿瘤中异常表达或突变,促进与细胞增殖和肿瘤发生相关的多种信号通路的启动,是肿瘤诊疗的重要靶点之一。核医学利用放射性示踪技术精确定位病灶,通过PET/SPECT显像技术实现肿瘤早期诊断及治疗监测。HER2放射性分子探针,包括抗体、小分子多肽、亲合体及锚蛋白重复蛋白等类型,正处于积极研发及临床前/早期临床研究阶段,为核医学领域研究热点之一。本文基于HER2放射性分子探针种类与乳腺癌、卵巢癌、胃癌等HER2阳性肿瘤疾病分类,对核医学技术应用于HER2阳性肿瘤诊疗的研究进展作一综述。

Human epidermal growth factor receptor 2(HER2),which is abnormally expressed or mutated in a variety of tumours,promotes the initiation of a variety of signalling pathways related to cell proliferation and tumourigenesis,and is one of the most important targets for tumour diagnosis and treatment.Nuclear medicine uses radiotracer technology to precisely locate lesions and PET/SPECT imaging to achieve early diagnosis and therapeutic monitoring of tumours.HER2 radiotracer probes,including antibodies,small molecule peptides,amphiphiles,and anchoring repeat proteins,are undergoing active research and development,and are one of the hotspots of research in the field of nuclear medicine.Based on the types of HER2 radioactive molecular probes and the disease classification of HER2-positive tumours,this paper reviewed the research progress of nuclear medicine technology applied to the diagnosis and treatment of HER2-positive tumours.